Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study.
<h4>Background</h4>Concerns about the high cost of orphan drugs has led to questions being asked about the generosity of the incentives for development, and associated company profits.<h4>Methods</h4>We conducted a retrospective, propensity score matched study of publicly-lis...
Saved in:
| Main Authors: | Dyfrig A Hughes, Jannine Poletti-Hughes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0164681&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Orphan drugs and the principles of their marketing authorization procedures and clinical use
by: A. A. Soldatov, et al.
Published: (2018-02-01) -
THE IMPACT OF MARKETING STRATEGY ON COMPANY EFFICIENCY AND PROFITABILITY
by: Zhanna B. Musatova
Published: (2017-09-01) -
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis.
by: Marcos Sterkel, et al.
Published: (2021-01-01) -
The clinical assessment of studies on orphan drugs in relation to the EMA’s authorization marketing decisions in Europe
by: Szczepan Jakubowski, et al.
Published: (2025-03-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)